INTRODUCTION
Newborn infants who acquire Herpes infections of the central nervous system (CNS) and/or disseminated disease historically have had a high incidence of poor neurologic outcomes. Outcomes have yielded only modest improvement with currently recommended courses of acyclovir (ACV) therapy and efforts to promote more rapid diagnosis and initiation of treatment. Reports of treatment outcomes for children cared for in the 1980s indicated that more than half of the infected children died and the majority of survivors had moderate-to-severe impairment. 1, 2 More recent reviews of infants receiving currently recommended acute therapy have found that the prognosis has not appreciably improved. 3 Common sequelae include microcephaly, hydrocephalus, cystic encephalomalacia, psychomotor retardation, spasticity, hemiparesis, quadriplegia, failure of language development, chorioretinitis, and blindness. 1 Initially, the CNS disease process was thought to be an acute neurologic insult that would be eradicated by acute ACV treatment. However, there has been evidence for several decades that infection may reactivate and cause recurrent symptomatic damage to the developing CNS. For example, Kimura et al. 4 followed 15 herpes simplex virus (HSV) polymerase chain reaction (PCR) positive patients: four had reactivation of HSV encephalitis after discontinuation of acute ACV therapy. We hypothesize that not all damage occurs initially, but rather that HSV of the CNS is similar to HSV disease of other sites in that subsequent recurrences may be prevented with prolonged administration of ACV, which in turn may improve neurodevelopmental outcomes. This report describes the results of a treatment plan that addresses the hypothesis.
METHODS

The Cohort
Parents of all infants with HSV infections of the CNS and/or disseminated disease known to the Pediatric Infectious Disease service at Duke University Medical Center (DUMC) during 1990 to 2003 were offered the treatment plan outlined below, and 17 infants with CNS and/or disseminated disease were enrolled. One family declined the treatment protocol. The cohort of 16 infants described in this article satisfied four inclusion criteria: (1) infection with HSV by a positive culture from a body site or at least one positive cerebrospinal fluid (CSF) PCR for HSV; (2) initial course of intravenous ACV for at least 21 days; (3) beginning oral ACV therapy at the completion of intravenous ACV; and (4) completing at least 1-year of the planned 2-year course of oral ACV therapy by the time this manuscript was in preparation. Patients were excluded due to parental refusal or perinatal death.
Neonatal herpes with CNS involvement was diagnosed by the presence of positive CSF culture or PCR for HSV. Alternative diagnostic criteria were supportive evidence of CNS disease including seizures or positive findings on electroencephalography (EEG), or focal magnetic resonance imaging (MRI) and/or computer-assisted tomography (CT), with a concurrent positive culture of the skin, eyes, or mucus membranes (SEM). Disseminated disease was diagnosed by the presence of HSV lesions plus elevated liver function tests or clinical symptoms consistent with shock. HSV typing was attempted on all infected infants.
Treatment Plan
Recommended initial therapy for infants diagnosed with neonatal herpes with CNS involvement and/or disseminated disease was intravenous ACV 1500 mg/m 2 /day for 21 days. Immediately following the completion of intravenous therapy, children were started on oral suspension of ACV. The planned duration of treatment was 2 years. The implementation of the present treatment plan required definition of each treatment component (LTG). These included expected HSV inhibitory concentrations of ACV, target minimum peak serum ACV concentrations, dosing required to reach ACV serum targets, methods of evaluating adequacy of dosing for each patient, duration of therapy, safety assessments, and outcome evaluations.
The bases for the decisions for each component were as follows. Guiding information was that an ACV concentration of approximately 1 mg/ml was required for the inhibition of HSV, and the ratio of CSF to blood ACV was approximately 30 to 50%. [5] [6] [7] [8] From this, target serum ACV concentrations of >2 mg/ml were initially selected and subsequently raised to >3 mg/ml for a wider therapeutic margin. In order to adequately determine individual treatment, dose-ranging information was collected and it was demonstrated that peak ACV levels >2 can be achieved with average doses of 1340 mg/m 2 /dose given at 12-hour intervals. 9 In order to assess the adequacy of dosing for each patient, serum samples for ACV concentration were drawn 1 h after a witnessed dose.
Starting oral doses for term or near-term newborns were 400 mg/dose given twice daily (approximately 1200 to 1600 mg/m 2 /dose). Doses were increased to the next greater 200 mg (tsp) when declining serum levels approached or fell below minimal target concentrations. For preterm infants, dosing was proportionally decreased, serum concentrations were assessed, and doses modified. Approximate doses for term infants by age were 400 mg for age 1 to 5 months, 600 mg for age 5 to 9 months, 800 mg for age 9 to 15 months, and 1000 mg for age 15 to 24 months (maximum dosage, 1200 mg). Any HSV isolates obtained during the course of therapy were to be typed and assayed for ACV sensitivity.
Patients were seen every 3 months by an infectious disease attending (LTG), to examine for medication adverse reactions, ACV serum concentrations, and to evaluate hematologic and renal function. Neurodevelopmental evaluations using Bayley Scales of Infant Development assessments for mental and for motor milestone achievement were completed at approximately 1 and at 2 years of age (KOD). 10 Bayley Scale score categories were as follows: significantly delayed <69; mildly delayed 70 to 84; within normal limits 85 to 114; and accelerated >115. Neurodevelopment outcomes for children were compared to historical controls from three reports published by the National Institute of Allergy and Infectious Disease (NIAID) Collaborative Antiviral Study Group.
2,3,11
We selected 2 years to be the duration of oral therapy for two reasons. We wished to provide therapy well beyond the intervals between acute therapy and instances of recurrence of which we were aware. Recurrences had occurred as late as 11 months after acute therapy in the children treated at DUMC in the decade prior to the development of this plan. Second, by age 2, developing language skills may enable parents and physicians to recognize early neurologic deterioration. IRB was consulted at the onset of the study, and in year 6, and IRB approval for oral consent was obtained. Parents were verbally informed that the recommended treatment plan involved use of an approved drug for an approved indication but at doses higher than standard and for a greater length of time. They were informed that minimal data regarding both safety and efficacy were available, which they might withdraw at will, and that relevant data would be made known to them as they emerged. Data were maintained within patient medical records.
We obtained Duke IRB approval to collect data using a standardized case report form for all infants with neonatal herpes with CNS involvement and/or disseminated disease over a 13-year period. The data were entered into a common database, and analyzed using STATA 8.1 (College Station, TX).
RESULTS
In all, 16 infants were enrolled into the treatment plan. Patient characteristics are shown in Table 1 . The median day of life that the infants were suspected of disease and ACV initiated was 15.5. Two infants had ACV started after day of life 30.
Diagnosis
Presenting symptoms of the infants with neonatal herpes were as follows: skin vesicles (12), temperature instability (10), seizures (five), shock (four), lethargy (three), ventilator dependence (three), poor suck (three), irritability (two), poor tone (one), apnea (one), and disseminated intravascular coagulation (one). Of the 16 infants, 13 were diagnosed with CNS disease. Diagnostic criteria are presented in Table 2 .
Eight infants with CNS disease had focal lesions by MRI and/or CT results. MRI results were as follows: multifocal abnormal MRI and EEG; abnormality in the basal ganglia; poor gray white matter distinction in the temporal lobe consistent with herpes cerebritis; hemorrhage and/or edema of the temporal lobe; hemispheric volume loss; and nonenhancing lesion in the subcortical white matter.
Outcome Two-year follow-up has been collected for 14 children and 1-year follow-up for 2 children. All children survived the treatment period. Bayley Scales administered at age 2 (patients 1 to 14) and at age 1 (patients 15 and 16) are the basis of the final developmental assessment (Tables 3 and 4) . At the final assessment, 69% (11/16) had Bayley Scores for mental development in the normal range. Five children had developmental delays. One child had severe mental delay with normal motor development. Four children had mild mental delays; of these, three had severe motor delays. The child with the lowest Bayley mental score (64) was microcephalic and had extensive cystic encephalomalacia. She was evaluated to be functioning socially, with normal motor development but delayed language development.
Normal motor developmental skills were noted in 79% (11/14) of children. Although three children had significant motor delay, all children were independent with mobility, regard to nutrition, without seizure disorder, with normal ocular control, and were Table 3 . Four infants were low birth weight (LBW) born weighing <2500 g (590, 1215, 2325, 2450 g) and the diagnosis of HSV infection ranged from 1 to 23 days of life.
Serum ACV assays were used to identify the need for dosing increases rather than to document maximal resting concentrations. The median of measured serum ACV concentrations was 2.7 mg/ml (range 0.8 to 7.0). Results of ACV assays were at or above target for 12 children, slightly below target for three, and less than 1 mg/ml for one child. Dosing was increased by 200 mg when a measured concentration approached or fell below target, but in order to avoid unnecessary phlebotomy of infants the study did not include repeat assays following increases in dose. For this reason, we do not further present the serum ACV data. With the possible exception of one child who we believed to be nonadherent to treatment, it did not appear that the children with transiently subtarget ACV concentration had worsened prognosis when compared with target concentrations.
Adverse drug reactions in this cohort were few and minor. One child had a single absolute neutrophil count of 767, the ACV dosing was continued without modification, and the neutropenia resolved within 1 week. Median absolute neutrophil count was 2774 (range 767 to 6160), median serum creatinine was 0.4 (range 0.3 to 0.5), and median blood urea nitrogen was 11 (range 8 to 18). One child had dental decay noted at the 2-year follow-up visit.
Adherence to therapeutic plan was estimated by history from caretakers and from the prescription refills. One child was believed to be seriously nonadherent, and that child had significant motor delay. In all, 15 children were receiving ACV as planned. The development of dermal irritations suggestive of possible early HSV eruption (three children) was an opportunity to reinforce adherence. The drug was well accepted by all children during the first year. Two children refused medication during the second year and completed the plan with crushed tablet formulation.
Dermal lesions during suppressive therapy were infrequent, minor, and did not progress to vesiculation. No infant was diagnosed with reactivation of CNS disease; no infant had acute neurological deterioration, and there was no clinical indication to examine CSF or obtain repeat imaging. No lesion was suitable for culture, and all resolved promptly with continuation of ACV at an unmodified dose. There was no evidence of failure to suppress HSV due to ACV resistance. 
DISCUSSION
In this study, infant survivors of CNS and/or disseminated disease had good outcomes. In all, 15 of 16 had accelerated, normal, or mild delay on mental achievement scores. It is noted that these scores included assessment for language skills, which testing at the usual follow-up period of 1-year could not have assessed. These outcomes compare very favorably with previous reports of children who received only acute therapy. Koskiniemi et al. 12 reported the outcomes of treatment of the first large series of children with neonatal herpes involving the CNS and disseminated disease treated with adenine arabinoside or ACV. Overall, 49% died or were neurologically damaged. Malm et al. 1 reported outcomes of children with various presentations of HSV disease. Of 45 children, 12 died during follow-up. Of the 33 survivors, 45% were quadraplegic or hemiplegic, 39% had severe mental retardation, 44% had ocular palsy, 37% had decreased visual acuity, and 30% had epilepsy. Overall, 33% were children who were well, 21% had moderate disabilities including hemiplegia and ocular abnormalities, and 33% had severe disabilities. 1 Studies from collaborating multicenter institutions and supported by NIAID Collaborative Antiviral Study Group were published in three reports.
2,3,11 Data on treatment of HSV and disseminated disease by adenine arabinoside and ACV were compared. 2 In these large, randomized studies, there were no significant differences in outcomes in the two treatment groups. For babies surviving the initial infection, only 21 of 58 with CNS disease (36%) were neurologically normal at 1 year, as were 59% of children with disseminated disease. Subgroups of infants with worse outcomes were those with seizures as a presentation, a delay in onset of therapy, and infection with HSV II.
In 2001, by which time effective antiviral therapy had been available for over 2 decades, 186 infants who had been treated between 1981 and 1997 during NIAID studies were reported by Kimberlin et al. 3 In that report, children treated during 1981 to 1988 were compared with those treated during 1989 to 1997 to determine if the outcomes had improved in the intervals. The conclusion was that minor progress had been made in decreasing the interval between onset of HSV symptoms and initiating antiviral therapy, and that shortening the interval was the sole means of improving the still dismal outcomes.
The population from NIAID studies, which was most closely comparable to the present series, received 45 or 60 mg ACV/kg/day for 21 days. 11 In the subgroups of children with CNS disease, only 30% were developing normally at 1 year as compared with our series in which 68% (11/16) were normal for both mental and motor development.
Four subpopulations of infants with CNS disease have been reported to worsen neurologic outcomes. These include prematurely delivered newborns, 12 infants with CSF positive for HSV by PCR, 13,14 children infected with HSV type II as compared with type I, 15, 16 and children presenting with seizures. 1, 3, 12, 15 Of the 16 children, 15 in this series had at least one of these higher risk findings, and nine children had two or more; accordingly, we believe that the greatly improved outcomes of the present series is not due to lesser severity of initial disease. In the present series, CSF was positive for HSV by PCR/culture in six of 16. Four (67%) were developmentally normal. This is in marked contrast with data from 1996 in which 68% of 26 children with those findings had moderate-to-severe disabilities or death. 13, 14 Adverse drug reactions were rarely observed in this cohort. This is consistent with large studies of patients receiving ACV over a period of 5 years. 17 In a review of the first 10 years of ACV use, no safety report caused a change in labeling, and no fatalities were reported in which ACV was felt to have played a causal role. 18 In the present series, no child had elevation of blood urea nitrogen or creatinine. No child had poorly responsive dermal HSV disease or evidence of development of an ACV-resistant strain. Symptomatic side effects were limited to two infants with dental decay including one with mild gastrointestinal symptoms. We attribute the dental decay to the sugar contained in the vehicle of the ACV suspension. Currently, we advise that children receiving chronic ACV therapy obtain the services of a pediatric dentist at eruption of the first tooth.
In addition to reports of benign reactions to ACV, there have also been reports of infants with neutropenia in association with ACV use. 19 In one child in the present series who had an absolute neutrophil count of 767, the ACV dose was continued, and the neutropenia resolved. Our findings are consistent with transient neutropenia that resolves despite continued ACV use observed previously, 20 and that of both antibiotic-treated and control infants in an earlier study of otitis media. 21 Although development of an ACV-resistant strain of HSV due to prolonged ACV is a potential concern, very large studies of longterm use of suppressive ACV for patients with recurrent genital HSV have looked for and failed to find an increase in ACV resistance. 20, 22 In the present small series, there was no evidence for this occurrence.
Limitations
This case series is without a direct comparative treatment group. Comparative data are instead derived from the well-reported historical information from multicenter studies of neonatal herpes. 1, 2, 3, 11, 15 The present study was conducted with children both from DUMC and children referred to Duke. Patient accrual was slow, approximately one to two a year. Nevertheless, a precise protocol was established at the onset with inclusion criteria and ACV treatment parameters. The treatment plan and assessment of neurodevelopmental outcomes were designed and conducted uniformly. Our opinion is that this approach to the therapy of neonatal herpes involving the CNS and/or disseminated disease should both be further evaluated and also be expanded to follow longer-term mental and motor development that may not have been apparent at 2 years.
Conclusion
In all, 69% of children demonstrated mental developmental scores in normal or accelerated ranges and 6% were severely delayed; 79% of children had normal motor developmental scores, and 21% were severely delayed. There were no drug reactions that were sustained or sufficiently serious so as to influence treatment. This series of children would have been at very high risk of moderate-to-severe disabilities had they had standard acute treatment alone. This experience indicates that further investigation of the use of this treatment plan as a strategy to improve long-term outcomes of infants with CNS and/or disseminated disease is warranted.
